

Oscotec Announces Closing of Series A Preferred Stock Financing with Korean and Japanese Institutional Investors

July 25, 2005 – Seoul, Korea – Oscotec, Inc. has closed a Series A Convertible Preferred Stock financing with a syndicate of Korean and Japanese institutional investors. The investor group included Japan Asia Investment Corporation., Ltd, Kibo Technology Advancing Capital Co., KB Investment Co. Ltd., and Boston Investment Co. The proceeds raised in the offering totals approximately \$3.2 million.

Oscotec is a bone specialized biotech company based in Korea. Oscotec is currently developing new drugs to treat Osteoporosis and Arthritis. In addition, the Company is selling several nutraceutical and functional ingredient products.

Roberts Mitani Advisors LLC advised Oscotec in this transaction. Roberts Mitani (www.robertsmitani.com) and its affiliated companies provide financial and strategic advisory services to emerging companies worldwide.